CN117813096A - 作为认知增强剂的line-1抑制剂 - Google Patents

作为认知增强剂的line-1抑制剂 Download PDF

Info

Publication number
CN117813096A
CN117813096A CN202280048917.1A CN202280048917A CN117813096A CN 117813096 A CN117813096 A CN 117813096A CN 202280048917 A CN202280048917 A CN 202280048917A CN 117813096 A CN117813096 A CN 117813096A
Authority
CN
China
Prior art keywords
line
inhibitor
subject
administered
cognitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280048917.1A
Other languages
English (en)
Chinese (zh)
Inventor
E·韦伯
A·萨特林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transposition Therapy Co ltd
Original Assignee
Transposition Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transposition Therapy Co ltd filed Critical Transposition Therapy Co ltd
Publication of CN117813096A publication Critical patent/CN117813096A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280048917.1A 2021-06-04 2022-06-03 作为认知增强剂的line-1抑制剂 Pending CN117813096A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163197015P 2021-06-04 2021-06-04
US63/197,015 2021-06-04
PCT/US2022/032120 WO2022256625A1 (en) 2021-06-04 2022-06-03 Line-1 inhibitors as cognitive enhancers

Publications (1)

Publication Number Publication Date
CN117813096A true CN117813096A (zh) 2024-04-02

Family

ID=84323626

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280048917.1A Pending CN117813096A (zh) 2021-06-04 2022-06-03 作为认知增强剂的line-1抑制剂

Country Status (10)

Country Link
US (1) US20240285664A1 (https=)
EP (1) EP4346835A4 (https=)
JP (1) JP2024520132A (https=)
KR (1) KR20240017910A (https=)
CN (1) CN117813096A (https=)
AU (1) AU2022283915A1 (https=)
CA (1) CA3221190A1 (https=)
IL (1) IL309036A (https=)
MX (1) MX2023014381A (https=)
WO (1) WO2022256625A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250170158A1 (en) * 2022-02-22 2025-05-29 Rome Therapeutics, Inc. Methods of treating medical conditions using censavudine or a related compound
WO2023178128A1 (en) * 2022-03-15 2023-09-21 Rome Therapeutics, Inc. Methods of treating medical conditions using islatravir or a related compound
WO2024107850A1 (en) * 2022-11-15 2024-05-23 Rome Therapeutics, Inc. Halo-dehydro-3'-deoxyuracil phosphoramidates and related compounds and their use in treating medical conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3302454T (pt) * 2015-05-26 2021-04-01 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composições para utilização no tratamento da doença de parkinson e distúrbios associados
EP3914604B1 (en) * 2019-01-25 2026-03-04 Brown University Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders
KR20230107543A (ko) * 2020-09-23 2023-07-17 트랜스포손 테라퓨틱스, 인코포레이티드 질병을 치료하기 위한 line-1 억제제

Also Published As

Publication number Publication date
MX2023014381A (es) 2023-12-15
EP4346835A4 (en) 2025-04-16
KR20240017910A (ko) 2024-02-08
IL309036A (en) 2024-02-01
EP4346835A1 (en) 2024-04-10
WO2022256625A1 (en) 2022-12-08
AU2022283915A1 (en) 2024-01-18
US20240285664A1 (en) 2024-08-29
JP2024520132A (ja) 2024-05-21
CA3221190A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
US11845739B2 (en) Solid forms of an HIV capsid inhibitor
AU2020202331B2 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an HIV virus infection
JP6933770B2 (ja) Ｈｉｖカプシド阻害剤のコリン塩形態
US20240018118A1 (en) Tricyclic compounds to degrade neosubstrates for medical therapy
CN117813096A (zh) 作为认知增强剂的line-1抑制剂
CN109906224B (zh) 三唑吡啶化合物及其应用
US11007174B2 (en) Pharmaceutical combination for the treatment of melanoma
JP2024511973A (ja) Ｃｎｓ疾患および全身性疾患を治療するためのｌｉｎｅ－１阻害剤
US11407747B2 (en) Compositions and methods for inhibiting kinases
ES3048138T3 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
EP3532065B1 (en) Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof
JP2022500471A (ja) キヌクリジン−３−オン化合物および癌治療へのその使用
TW202003518A (zh) 用於肝癌之治療及預防之7–經取代磺醯亞胺醯基嘌呤酮化合物及衍生物
CN108348524A (zh) 用于从中风恢复的方法和组合物
US20180179178A1 (en) Selective anti-cancer compounds
US11717511B2 (en) Pharmaceutical composition comprising derivative compound of 1,2-naphthoquinone for preventing or treating solid cancer or blood cancer
WO2019139399A1 (ko) Pi3 키나아제 억제제 및 세포독성 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물
HK40083477A (en) Solid forms of an hiv capsid inhibitor
HK40083477B (en) Solid forms of an hiv capsid inhibitor
CA3152424A1 (en) Quinoline inhibitors of rad52 and methods of use
CN108976235A (zh) 一种喹唑啉酮类化合物及其用途
HK40019949A (en) Solid forms of an hiv capsid inhibitor
WO2009110416A1 (ja) 併用剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination